Formulation Development
POLYMACROCYCLIC PEPTIDES - Engineering Structure for Function in Next Generation Therapeutics
Karsten Eastman, PhD, and Vahe Bandarian, PhD, believe the key challenge, and opportunity, is to sculpt peptide architecture so that shape and chemistry are presented to the target in the right place, at the right time, and for long enough to matter clinically.
TECHNOLOGY TRANSFER - Streamlining Biologics Technology Transfer Through Integrated Operational Models
Lalit Saxena explains how technology transfer in biologics manufacturing is an inherently complex process that requires the simultaneous control of multiple scientific, technical, and operational variables.
THERAPEUTIC FOCUS - Advancing Adjunctive Therapies for Depression & OCD Using Translational Pharmaceutics®
Jacob Jacobsen, PhD, Bret Berner, PhD, and Vanessa Zann, PhD, review a partnership with Evecxia Therapeutics to support the development of EVX-101, an investigational adjunctive drug for depression and obsessive-compulsive disorder (OCD) responding inadequately to first-line antidepressants.
RADIOLIGAND THERAPIES - Affibody Molecules: A Versatile Approach to Radiopharma
Fredrik Frejd reviews Affibody’s lead RLT candidate, ABY-271, currently being evaluated in a first-in-human clinical study in HER2 positive metastatic breast cancer.
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head & Neck Cancer
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the completion of patient randomization…
PannTheraPi Announces Significant Clinical Development & Strategic Milestones
PannTheraPi recently announced significant progress in its clinical development alongside a key leadership appointment to strengthen its scientific and operational capabilities. The company has submitted…
ProImmune Collaborates With The University of Texas Medical Branch to Advance Infectious Disease Research
ProImmune, Ltd.recently announced a collaboration with The University of Texas Medical Branch (UTMB) Galveston National Laboratory (GNL), a high-containment, infectious disease research facility, to develop…
Symbiosis Expands Commercial Capabilities With Addition of New Stability Chamber
Symbiosis Pharmaceutical Services has expanded its Quality Control (QC) laboratory with the installation of a new 30°C stability chamber. This addition enables Symbiosis to replicate…
Alzheon Advances Next-Gen Pipeline With First Patient Dosed in ALZ-507 Study
Alzheon, Inc. recently announced the dosing of the first cohort of human volunteer subjects in a Phase 1 single and multiple ascending dose clinical trial of…
Cereno Scientific Reports Robust Safety & Tolerability in Long‑Term CS1 Pulmonary Arterial Hypertension Study
Cereno Scientific provides additional context on the safety and tolerability data from up to 12 months of treatment from the Expanded Access Program (EAP) with…
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
ANI Pharmaceuticals, Inc. recently announced publication of the results from the NEW DAY clinical trial involving ILUVIEN (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for…
FORE Biotherapeutics Receives Breakthrough Therapy Designation for Plixorafenib
FORE Biotherapeutics, a registration-stage company dedicated to developing targeted therapies to treat patients with cancer, today announced that the U.S. Food and Drug Administration (FDA)…
Adragos Pharma Finalizes the Acquisition of Commercial-Scale, Sterile Fill-Finish Manufacturing Site From Sanofi
Adragos Pharma recently announced it completed the acquisition of a commercial-scale sterile fill-finish facility in Maisons-Alfort, France, from Sanofi. The Maisons-Alfort site is one of…
Cyclerion Therapeutics & Korsana Biosciences Announce Merger Agreement
Cyclerion Therapeutics, Inc. and Korsana Biosciences, Inc. recently announced they have entered into a definitive merger agreement for an all-stock transaction. Upon completion of the…
Amprion Grows Global Footprint With Australian Partnership & Expanded Research Collaborations
Amprion recently announced a series of strategic milestones that underscore the company’s accelerating growth, expanding international footprint, and continued commitment to advancing earlier and more accurate…
Samsung Biologics Completes Acquisition of GSK’s Manufacturing Facility
Samsung Biologics recently announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in…
Symeres & Ambagon Therapeutics Collaborate on Molecular Glue Research in Colorectal Cancer
Symeres has recently partnered with Ambagon Therapeutics, a pre-clinical biotechnology company, to explore a new class of small molecules, known as molecular glues, for potential…
ImmuneOncia Therapeutics & Lonza Collaborate to Manufacture a PD-L1 Antibody Targeting Immuno-Oncology
ImmuneOncia Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on immuno-oncology, and Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced today…
Vetter Recognized as 2026 CDMO Leadership Awards Winner
Vetter receives recognition as CDMO of the year in the category “Finished Dose” of the 2026 CDMO Leadership Awards. The award honors the company for…
Quotient Therapeutics Announces Collaboration With Merck to Discover Novel Drug Targets in Inflammatory Bowel Disease Using Somatic Genomics Platform Technology
Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has entered a multi-year research collaboration agreement with Merck, known…
